It has also been demonstrated that the expression levels of CEACAM6 are higher than those of CEA in malignant tumors including breast cancer, lung cancer, prostate cancer, colon cancer, pancreatic cancer, and ovarian cancer. Here, CEACAM6 is linked to ovarian carcinoma.